Skip to main content


You are here

AIkido Provides Update on Use of Machine Learning in Drug Development Program

Friday, August 6, 2021

PR Newswire

NEW YORK , Aug. 6, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided and update on the use of Machine Learning in support of its antiviral platform with the University of Maryland Baltimore School of Medicine.  The Company stated:

The goal for the project is the identification and optimization of anti-viral compounds that inhibit viral replication by targeting a protein complex that degrades RNA at the cellular level.  To support this goal, physics-based machine learning (ML) is being applied by SilcsBio LLC to accelerate the discovery of broad-spectrum antivirals.  These efforts are targeting the human SKI complex that is involved in the replication of RNA viruses from which multiple drug candidates have been identified and shown to be effective against SARS-CoV-2 as well as other coronaviruses, including MERS-CoV, Influenza viruses and the filoviruses Ebola and Marburg. Ongoing efforts involve further development of those drug candidates using the SILCS data-driven ML ligand optimization approach in conjunction with medicinal chemistry, biophysical characterization, and cell- and animal-based antiviral experimental evaluation. These collaborative efforts will yield novel chemical entities to be considered for investigational new drug (IND) status and clinical trials leading to therapeutic agents poised to take on the next global pandemic.

Read the full release from AIkido Pharma.